机构投资者在"适度购买"前景下增加了糖尿病设备制造商德克斯康的股份. Institutional investors boost stakes in DexCom, a diabetes device maker, amid a "Moderate Buy" outlook.

芝加哥资本有限公司和其他机构投资者增加了DexCom公司的股份,DexCom公司是一家医疗设备公司,开发糖尿病连续葡萄糖监测系统。 Chicago Capital LLC and other institutional investors have increased their stakes in DexCom, Inc., a medical device company that develops continuous glucose monitoring systems for diabetes. DexCom的股票目前为各机构拥有的多数人所拥有,其评级有好有坏,但总体前景是乐观的,一致的“多价买入”评级,目标价格约为98.41美元。 DexCom’s stock, currently majority-owned by institutions, has seen mixed analyst ratings but generally positive outlooks, with a consensus "Moderate Buy" rating and a target price of around $98.41. 最近的内幕销售和各种机构投资反映了公司对市场的持续兴趣。 Recent insider sales and varying institutional investments reflect ongoing market interest in the company.